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Abstract
Background: Exercise seems to minimize prostate cancer specific mortality risk and treatment related side effects
like fatigue and incontinence. However the influence of physical activity on the immunological level remains
uncertain. Even prostate cancer patients undergoing palliative treatment often have a relatively long life span
compared to other cancer entities. To optimize exercise programs and their outcomes it is essential to investigate
the underlying mechanisms. Further, it is important to discriminate between different exercise protocols and
therapy regimes.
Methods/Design: The ProImmun study is a prospective multicenter patient preference randomized controlled trial
investigating the influence of a 24 week endurance exercise program in 80–100 prostate cancer patients by
comparing patients undergoing Antiandrogen therapy combined with exercise (AE), Antiandrogen therapy without
exercise (A), Chemotherapy with exercise(CE) or Chemotherapy without exercise (C). The primary outcome of the
study is a change in prostate cancer relevant cytokines and hormones (IL-6, MIF, IGF-1, Testosterone). Secondary
endpoints are immune cell ratios, oxidative stress and antioxidative capacity levels, VO2 peak, fatigue and quality of
life. Patients of the intervention group exercise five times per week, while two sessions are supervised. During the
supervised sessions patients (AE and CE) exercise for 33 minutes on a bicycle ergometer at 70-75% of their VO2 peak.
To assess long term effects and sustainability of the intervention two follow-up assessments are arranged 12 and
18 month after the intervention.
Discussion: The ProImmun study is the first trial which primarily investigates immunological effects of a six month
endurance exercise program in prostate cancer patients during palliative care. Separating patients treated with
Antiandrogen therapy from those who are additionally treated with Chemotherapy might allow a more specific
view on the influence of endurance training interventions and the impact of different therapy protocols on the
immune function.
Trial registration: German Clinical Trials Register: DRKS00004739
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Within the last decade, an increasing number of studies
were able to demonstrate that physical activities in gen-
eral, as well as defined and controlled exercise programs
are beneficial for prostate cancer patients. Kenfield and
colleagues [1] provided evidence that regular physical
activity may reduce overall mortality and prostate cancer
specific mortality. Other well designed studies show
a positive influence of exercise interventions regarding
treatment related side effects like urinary incontinence
after surgery [2,3] and body composition changes dur-
ing Antiandrogen therapy [4]. Positive effects of exer-
cise on general cancer- and cancer therapy associated
symptoms like fatigue could have been detected as well
[5]. Finally physical activity increases the endurance cap-
acity, muscular strength and quality of life in prostate can-
cer patients independent of their stage of disease [6-9].
Most of the underlying mechanisms leading to the de-
scribed desirable effects of physical activity are poorly in-
vestigated. In order to optimize the outcome of exercise
interventions, future research has to reveal the systemic in-
fluence of physical activity on the molecular and cellular
level. As in drug development, dose-effect relationships will
play a key role in creating exercise programs. Since exercise
programs and their systemic effects differ enormously (e.g.
intensities, frequencies and type of exercise), it is essential
to investigate them separately. This should also be consid-
ered when regarding exercise interventions with different
cancer entities and during different medical treatment re-
gimes. A first approach to learn more about the cellular ef-
fects of a defined resistance exercise program in prostate
cancer patients undergoing Antiandrogen therapy has been
presented by Thorsen et al. [10]. However this study fo-
cuses on the influence of strength training on muscle tissue
and body composition.
Knowledge about the impact of physical activity on the
tumor, tumor relevant growth factors and the immune
system is still rudimental. In a pilot study we investi-
gated the influence of a 1408 km bicycle tour on Testos-
terone, Interleukin 6 and PSA levels in prostate cancer
patients. In accordance with the results by Segal et al.
[6], we found a decrease in Testosterone levels whereas
the other Parameters did not change [11]. Only a few
studies with humans have focused on the impact of exer-
cise interventions on Cytokine levels or immune cells in
cancer patients. Furthermore, these studies primarily fo-
cused on breast cancer patients [12-14]. In order to
present possible connections between prostate cancer,
exercise and the genesis or the progression of the dis-
ease, we would like to highlight three animal studies.
Teixeira et al. [15] were able to show that endur-
ance exercise has the potential to induce changes in
sex hormone levels and sex hormone receptors in the
ventral prostate of healthy rats. Exercising animals showed
increased levels of Corticotestosterone, Dihydrotestoster-
one, Testosterone and Estrogen receptors whereas An-
drogen receptors decreased. In contrast to the control
group, exercising animals showed a modified proliferation-
apoptosis ratio with a shift toward apoptosis. Jones and
colleagues [16] presented a prostate cancer mouse model.
In this study, tumor growth rates did not differ between
animals in the exercising group and those in the control
group. Interestingly a significant reduction of the expres-
sion of prometastasic genes could be observed in the exer-
cising animals. Exercise also seemed to stabilize the tumor
vascular system, leading to an improved endothelial barrier
which may constrict the migration of metastatic cells. Fi-
nally Zheng et al. [17] suggest that exercise may inhibit the
progression of advanced prostate cancer cells, leading to a
delayed Androgen independency of the disease. Exercising
mice showed a 38% decrease in mitotic cell/caspase 3 posi-
tive tumor cell ratio and featured a reduced increase of
IL-6. IL-6 is discussed to be needed by the tumor cells in
order to become Androgen independent. Regarding the
described effects, exercise was even more effective when it
was combined with a caffeine substitution. Chronic and
acute exercise induced IL-6 alterations are also well de-
scribed in humans [18].
Within the ProImmun trial we would like to focus on
the influence of a six month supervised endurance exer-
cise program on prostate cancer relevant cytokines and
immune function in patients with advanced prostate can-
cer undergoing Antiandrogen therapy or Antiandrogen
therapy in combination with chemotherapeutic agents.
As described above [12-14] endogenous tumor defense
might be stimulated by physical activity, and therefore
lead to an improved outcome in terms of relapse- and
mortality risk. We expect that an enhanced immune
function may help to stabilize even advanced stages of
prostate cancer.
Methods/Design
The ProImmun study was planned as a four arm, pro-
spective multicenter preference randomized trial. For this
purpose a collaboration consisting of the Department of
Molecular and Cellular Sports Medicine of the German
Sport University Cologne, the community of private prac-
ticing urologists at cologne (KCU) and the Department of
Oncology and Hematology of the Hospital Northwest at
Frankfurt was installed. All patients will provide written in-
formed consent prior to participation. The study protocol
has been approved by the ethics committee of the German
Sport University Cologne and the ethics committee of the
Krankenhaus Nordwest at Frankfurt (Figure 1).
Subjects and sample size calculation
Regarding changes in cytokine levels and immune cell
compartments through physical activity no effect size is
Zimmer et al. BMC Cancer 2013, 13:272 Page 2 of 6
http://www.biomedcentral.com/1471-2407/13/272known for patients suffering from advanced prostate can-
cer. Even for other cancer entities and diseases in combin-
ation with exercise programs effect sizes of the named
factors are not alienable due to different therapies or vary-
ing exercise programs. This circumstance would lead to an
imprecise, ambiguous sample size calculation. Therefor we
decided to choose a sample size which enables us to per-
form descriptive statistic tests (e.g. T-tests, variance ana-
lyses) with 20–25 patients in each of the four groups.
Inclusion and exclusion criteria (Table 1)
Recruitment
In a first step, private urologists in cologne and physi-
cians at the Department of Oncology and Hematology of
the Hospital Northwest in Frankfurt screen all potential
study participants and provide oral information about
the intervention study. If a patient is interested, assigned
consent is passed on the local study coordination, which
will contact the patient. In a second step, agreeing sub-
jects receive written information material and are invited
for a preliminary conversation and baseline testing. Prior
to baseline testing, patients have to provide written con-
sent to participate in the study.
Randomization
In accordance with the principles of a patient preference
trial, only patients who do not have a strong group pref-
erence will be randomized into either the exercise or the
control group using the RITA randomization software
(STATSOL.de) [19-21].
Intervention
Subjects, participating in the intervention group exer-
cise five times per week for six months. Two exercise
Figure 1 Study design with patient enrolment and measurement time points.
Table 1 Inclusion and exclusion criteria
Inclusion criteria Exclusion criteria
￿ Patients with advanced prostate
cancer receiving Antiandrogen
therapy for at least 4 weeks or
￿ Anemia>8 g/dl
￿ Platelet count≤10000/μl
￿ COPD
￿ Patients with advanced prostate
cancer receiving Antiandrogen
therapy in combination with
chemotherapy (baseline test
before chemotherapy)
￿ CNS Metastasis
￿ Epilepsy
￿ Planned Surgery
￿ Heart failure (NYHA III-IV)
￿ Hemoglobin>9 g/dl ￿ Coronary disease
￿ Ejection fraction≥60% ￿ Therapy refractory Hypertension
￿ Forced expiratory volume in
one second≥50%
￿ Other internistic diseases that rule
out exercise
￿ Orthopedic handicaps that rule
out exercise
￿ Age≥18 years ￿ Psychological problems which are
critical in view of the responsible
medical doctor ￿ Expectation of life≥6 month
￿ Written consent
￿ Inconspicuous ultrasound of the
patients heart
￿ Inconspicuous ECG (rest and stress)
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sions, patients exercise for 33 minutes on a bicycle
ergometer (ergoline, Bitz). After a three minute warm
up, individuals exercise for 25 minutes at 70-75% of
their VO2p e a k , followed by a 5 minute cool-down.
The other three exercise sessions per week are conducted
home based. Patients are asked to exercise at for least
15 minutes per session and complete an exercise diary.
Participants can choose their preferred type of endur-
ance exercise (e.g. walking, nordic-walking, swimming).
In order to control the home based sessions, patients
are informed about their exercising heart rate range
according to their preferred type of endurance exercise.
T h ee x e r c i s ei n t e n s i t i e sc o m p l yw i t ht h o s eo ft h es u p e r -
vised sessions.
Measurement time points
All outcomes of the study will be assessed five times in
each group. After the initial baseline testing (T0), partic-
ipants are tested after three month (T1). This examin-
ation is also used to readjust the intensity of the exercise
program in the intervention group. The third assessment
is arranged after the six month intervention (T3). Two
follow-up measurements are conducted six month (T4)
and twelve month (T5) after the end of the intervention.
Primary endpoint
Cytokine/hormone levels IL-6, Macrophage migration
inhibiting factor (MIF), Testosterone and Insluin like
growth factor 1 (IGF-1) levels will be measured via ELISA
as soon as the study is completed. Therefore, venous blood
samples will be collected and frozen away. All named me-
diators seem to be involved in tumor growth and disease
progression. Additionally these cytokines and hormones
can be influenced by physical activity [22-25].
Secondary enpoints
Immune function
To evaluate the immune function, flow cytometer analyses
using a 4 four color BD FACS Array Cytometer are carried
out at all time points. Different cluster of differentiation
(CD) antibodies, including CD3, CD4, CD8, CD16, CD19,
CD25, CD45, CD127 are used to evaluate the number of
diverse T-cell compartments, B- and NK-cells.
Oxidative stress/Antioxidative capacity
On the one hand, raised oxidative stress levels have been
described to be involved in the development of chronic
diseases, e.g. cancer, and disease progression [26]. On
the other hand, the effects of some chemotherapeutic
drugs are based on the induction of oxidative stress [27].
Physical activity seems to influence oxidative stress levels
and antioxidative capacity in prostate cancer patients
[28]. Within the ProImmun trial general oxidative stress
levels and antioxidative capacity are measured in peripheral
blood samples using a colorimetric procedure (FORMplus,
Incomat, Glashütten, Germany).
Endurance capacity
In order to measure endurance capacity, a modified
WHO bicycle spiroergometer test is performed at each
measuring time point named above. Patients start cyc-
ling at 30 Watt while the power increases by 15 Watt
every two minutes. Patients work out until respiratory
exhaustion sets in. The VO2 peak (highest O2 consump-
tion during the test) is used to control the exercise inter-
vention and to assess the endurance capacity.
Physical activity levels
Physical activity levels are assessed by two different
methods. As in most exercise interventions we decide
to apply an evaluated German questionnaire (Freiburger
Questionaire of Physical Activity) which identifies MET-
scores [29]. Additionally all patients receive an ADL-
monitor (Sensewear, Bodymedia), combining pedometer
data, changes in temperature flow and galvanic skin re-
sponse. Patients wear the ADL-monitors four times during
the study period, always for one week.
Psychological and psycho-social assessments
Aside from investigating of physiological factors, we are
interested in the influence of the intervention on Quality
of life, prostate cancer specific problems, like incontinence
and fatigue. Therefor the EORTC-QLQ-C30, its prostate
cancer specific module PR-25 and the Multidemensional
Fatigue Inventory (MFI-20) are full filled by the patients to
all named time points [30-32].
Discussion
The ProImmun trial is probably the first attempt to in-
vestigate the influence of a well-defined and practicable
exercise intervention on the immune system of patients
with advanced prostate cancer. It may provide several
new hints regarding the impact of an endurance exercise
program on cytokine levels, immune function and oxida-
tive stress levels. Combining these data with those of dis-
ease progression and cancer (therapy) related symptoms
like fatigue, may help to obtain new mechanistic insights.
Even if these hints will not provide detailed information
about downstream mechanism (e.g. signal transduction),
they could serve as an “ door opener” for further research.
Despite the exercise program, our study design has the
potential to indicate whether different therapy protocols
have a different impact on the reported immunological
parameters. To the best of our knowledge, so far only
one study has focused on the influence of exercise on a
wide range of cytokine levels in cancer patients [22].
However individuals who participated in this comparably
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ate intensities. Furthermore, the participants were breast
cancer patients who exercised after having completed med-
ical therapy. Finally, changes in cytokine levels were only
combined with psycho-social parameters (e.g. Fatigue
questionnaires) [33].
Separating patients who are treated with Antiandrogen
therapy from those who are additionally treated with
Chemotherapy may help to understand, whether the inter-
vention has the same effect in both groups. Therewith, we
get us one step closer to the final aim of cancer (stage) spe-
cific exercise programs. In order to gain more knowledge
about the mode of action and dose-effect relationships, fur-
ther studies need to consider different kind of exercise in-
tensities and exercise types as presented by Santa Mina
and colleagues [34].
Finally the two follow-up measurements will provide
information regarding the sustainability of the exercise
program. Since even patients with advanced prostate
cancer have a relatively long life expectancy, we will in-
vestigate whether the intervention leads to long-term
changes regarding all endpoints.
In a next step, scientists should start combining these
factors. From a more experimental point of view, future re-
search also has to focus on the influence of different exer-
cise types and intensities on the tumor itself. It will be
challenging to transfer the results of these studies on hu-
man beings and generate applicable exercise programs, as
mentioned in the introduction section [15-17]. In contrast
to other studies [35,36] the intensity and frequency of our
endurance exercise intervention (75% of VO2p e a k ) is rela-
tively high. Comparing the outcomes of our study to those
of other endurance exercise interventions, e.g. walking pro-
grams, may allow at least first conclusions regarding the
impact on outcomes like fatigue and quality of life.
For most patients, quality of life and other psycho-
social factors are important motivational aspects to par-
ticipate in exercise programs. Presumably the positive
influence on these factors can only partly or indirectly
be explained by physiological parameters. However, since
the knowledge about physical activity, prostate cancer
disease progression and prostate cancer specific mortal-
ity risk is increasing [1], it will be a major concern to
optimize and specify exercise programs. Therefore it is
essential to learn more about exercise induced effects on
tumor competitive immune cells and tumor-host rele-
vant mediators like cytokines.
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